Pacira (PCRX) BioSciences announced the receipt of U.S. Patent No. 12,156,940 from the U.S. Patent and Trademark Office, the U.S. PTO. The ‘940 patent, entitled “Manufacturing of Bupivacaine Multivesicular Liposomes” protects the chemical composition of EXPAREL. This patent is the first patent from a new family of patents related to EXPAREL produced by the company’s enhanced large-scale manufacturing process in San Diego, which received approval from the U.S. Food and Drug Administration in February 2024. The company expects the ‘940 patent to provide protection into July 2044.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PCRX:
- Pacira announces 104-week safety, efficay data for PCRX-201
- Pacira price target lowered to $17 from $25 at Barclays
- Pacira price target raised to $12 from $11 at Piper Sandler
- Pacira BioSciences Reports Q3 2024 Earnings and Strategic Developments
- Pacira Pharmaceuticals Faces Q3 Loss Amid Revenue Growth
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
